The "Global Biopsy Device Market, Biopsy Procedure Volume, Company Product Analysis and Forecast To 2022" report has been added to ResearchAndMarkets.com's offering.

The global market for biopsy devices is anticipated to reach around US$ 2 Billion by 2022.

The biopsy device market will experience considerable growth over the forecast period, driven by an increasing prevalence of cancer, geriatric population and increasing demand for minimally invasive procedures are expected to drive market growth during the forecast period. Growing patient awareness levels and the advancement in biopsy techniques are also expected to fuel future growth of the market.

The market for biopsy guidance systems held the largest share in 2017 and is expected to continue to lead the market throughout the forecasting period. It is expected that the needle based guns market share will increase to nearly 40% by 2022. Vacuum-assisted biopsy devices represent the fastest growing segment, and increased medicare reimbursement given for such procedures is expected to help fuel demand. Forceps and other devices are expected to account for lesser shares as compared to the other segments, due to their specific applications and also risks associated with their use.

United States is the largest regional market for biopsy devices. China is the second leading market for biopsy devices being followed by India. Brazil accounted for over 5% share of the global biopsy devices market in 2017. The EU5 countries accounted for a combined share of over 15% in 2017. Among the European countries, Germany is the leading market for Biopsy devices.

Market Dynamics

Driving Factors

  • Increasing preference for minimally invasive biopsy procedures
  • Inadequate Screening Tests for Particular Cancers
  • Increasing incidence of cancer cases worldwide
  • Rapidly aging global population
  • Rising public awareness about diseases and screenings conducted for the same
  • Advancement in Biopsy Techniques

Challenges

  • Clinical Issues in The Core Needle Biopsy
  • High pricing of technologically advanced biopsy devices
  • Biopsy Limitations

Companies Mentioned

  • Argon Medical Devices
  • Boston Scientific
  • C. R. BARD, Inc (Acquired by Becton, Dickinson and Company)
  • Carefusion Corporation (Acquired by Becton, Dickinson and Company)
  • Cook Medical
  • Devicor Medical Products Inc.
  • Gallini Medical Devices
  • Hologic, Inc
  • INRAD, Inc
  • Intact Medical Corporation (Acquired by Medtronic)
  • TSK Laboratory

For more information about this report visit https://www.researchandmarkets.com/research/6293k2/global_2_billion?w=4